...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of diabetes. >Saxagliptin alters bile acid profiles and yields metabolic benefits in drug‐na?ve overweight or obese type 2 diabetes patient
【24h】

Saxagliptin alters bile acid profiles and yields metabolic benefits in drug‐na?ve overweight or obese type 2 diabetes patient

机译：Saxagliptin改变胆汁酸概要文件和产量代谢药物na应承担的好处?肥胖的2型糖尿病病人

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Background The aim of the present study was to investigate the metabolic benefits of saxagliptin and its effects on serum bile acids (BAs) in normal weight and overweight/obese drug‐na?ve type 2 diabetes (T2D) patients. Methods In all, 282 drug‐na?ve T2D patients (123 normal weight [NW], with body mass index [BMI] between 19.0 and 25.0 kg/m 2 ; 159 overweight/obese [OW/OB], with BMI ≥25.0 kg/m 2 ) were enrolled in the study and treated with saxagliptin 5 mg daily for 24?weeks. Serum BAs were assayed by liquid chromatography with tandem mass spectrometry. Results At 24?weeks, HbA1c was significantly reduced in both groups, but the HbA1c levels were lower in the OW/OB than NW group. Moreover, significant decreases were seen at 24?weeks in C‐reactive protein (CRP), aspartate aminotransferase, alanine aminotransferase, waist circumference, and systolic blood pressure in the OW/OB group. Interestingly, cholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid (GDCA), and glycoursodeoxycholic acid (GUDCA) were increased in both groups after treatment, whereas chenodeoxycholic acid and deoxycholic acid (DCA) were specifically increased in the OW/OB group. Increased DCA and GDCA concentrations were significantly associated with decreased HbA1c or fasting blood glucose and CRP levels, whereas increased GDCA and GUDCA concentrations were associated with decreased waist circumference in the OW/OB group during treatment. In the NW group, increased GUDCA concentrations were significantly associated with a decrease in HbA1c. Conclusions Type 2 diabetes patients with OW/OB exhibited greater improvement in glycemic control and additional metabolic benefits after saxagliptin treatment. Saxagliptin significantly increased the BA pool, and DCA and GDCA were associated with metabolic improvements in OW/OB T2D patients.
机译：抽象的背景目前研究的目的探讨代谢的好处吗对血清胆汁酸saxagliptin及其影响(BAs)在正常体重,超重/肥胖药物量na ?方法,282药物所致na ?正常体重(西北),身体质量指数(BMI)19.0到& 25.0公斤/米2;(噢/ OB)超重/肥胖,体重指数≥25.0公斤/米2)为研究和治疗saxagliptin 5毫克每日24吗?周。化验了液相色谱串联质谱分析。在两组显著降低,但噢/ OB糖化血红蛋白水平低于西北组。在24吗?天冬氨酸转氨酶,丙氨酸转氨酶、腰围和噢/ OB组收缩压。有趣的是,胆酸,glycocholic酸,glycochenodeoxycholic酸,glycodeoxycholic酸(GDCA)和glycoursodeoxycholic酸(GUDCA)治疗后两组中均有增加,而鹅去氧胆酸和脱氧胆酸(DCA)特别的增加噢/ OB组。浓度都显著相关降低糖化血红蛋白和空腹血糖和CRP的水平,而增加GDCA和GUDCA浓度与减少有关噢/ OB组在腰围治疗。浓度都显著相关糖化血红蛋白的下降。噢/ OB患者表现出更大的改进在血糖控制和额外的代谢福利saxagliptin治疗后。显著增加英航池,DCA和GDCA与代谢有关的改进噢/ OB T2D的病人。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号